Skip to main content
Journal cover image

The Effect of Perimenopausal Transdermal Estradiol and Micronized Progesterone on Markers of Risk for Arterial Disease.

Publication ,  Journal Article
Gordon, JL; Rubinow, DR; Watkins, L; Hinderliter, AL; Caughey, MC; Girdler, SS
Published in: J Clin Endocrinol Metab
May 1, 2020

BACKGROUND: The arterial effects of hormone therapy remain controversial. This study tested the effects of transdermal estradiol plus intermittent micronized progesterone (TE + IMP) in healthy perimenopausal and early postmenopausal women on several mechanisms involved in the pathophysiology of arterial disease. METHODS: Healthy perimenopausal and early postmenopausal women, ages 45 to 60 years, were enrolled in this randomized, double-blind, placebo-controlled trial. Women were randomized to receive TE (0.1 mg/day) + IMP (200 mg/day for 12 days) or identical placebo patches and pills for 12 months. Outcomes included: change in stress reactivity composite z-score (combining inflammatory, cortisol, and hemodynamic responses to a standardized psychological laboratory stressor); flow-mediated dilation (FMD) of the brachial artery (an index of vascular endothelial function); baroreflex sensitivity; and metabolic risk (presence of the metabolic syndrome or insulin resistance), all assessed at baseline and at months 6 and 12. RESULTS: Of 172 women enrolled, those assigned to TE + IMP tended to have higher resting baroreflex sensitivity than those assigned to placebo across the 6- and 12-month visits. Although treatment groups did not differ in terms of the other prespecified outcomes, a significant treatment-by-age interaction was found for FMD and stress reactivity such that an age-related decrease in FMD and increase in stress reactivity were seen among women assigned to placebo but not those assigned to TE + IMP. Women on TE + IMP also had lower resting diastolic blood pressure, lower levels of low-density lipoprotein cholesterol, and higher baroreflex sensitivity during stress testing. CONCLUSIONS: TE + IMP tended to improve cardiac autonomic control and prevented age-related changes in stress reactivity and endothelial function among healthy perimenopausal and early postmenopausal women.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Clin Endocrinol Metab

DOI

EISSN

1945-7197

Publication Date

May 1, 2020

Volume

105

Issue

5

Start / End Page

e2050 / e2060

Location

United States

Related Subject Headings

  • Vascular Diseases
  • Treatment Outcome
  • Transdermal Patch
  • Risk Factors
  • Progesterone
  • Placebos
  • Perimenopause
  • Middle Aged
  • Humans
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gordon, J. L., Rubinow, D. R., Watkins, L., Hinderliter, A. L., Caughey, M. C., & Girdler, S. S. (2020). The Effect of Perimenopausal Transdermal Estradiol and Micronized Progesterone on Markers of Risk for Arterial Disease. J Clin Endocrinol Metab, 105(5), e2050–e2060. https://doi.org/10.1210/clinem/dgz262
Gordon, Jennifer L., David R. Rubinow, Lana Watkins, Alan L. Hinderliter, Melissa C. Caughey, and Susan S. Girdler. “The Effect of Perimenopausal Transdermal Estradiol and Micronized Progesterone on Markers of Risk for Arterial Disease.J Clin Endocrinol Metab 105, no. 5 (May 1, 2020): e2050–60. https://doi.org/10.1210/clinem/dgz262.
Gordon JL, Rubinow DR, Watkins L, Hinderliter AL, Caughey MC, Girdler SS. The Effect of Perimenopausal Transdermal Estradiol and Micronized Progesterone on Markers of Risk for Arterial Disease. J Clin Endocrinol Metab. 2020 May 1;105(5):e2050–60.
Gordon, Jennifer L., et al. “The Effect of Perimenopausal Transdermal Estradiol and Micronized Progesterone on Markers of Risk for Arterial Disease.J Clin Endocrinol Metab, vol. 105, no. 5, May 2020, pp. e2050–60. Pubmed, doi:10.1210/clinem/dgz262.
Gordon JL, Rubinow DR, Watkins L, Hinderliter AL, Caughey MC, Girdler SS. The Effect of Perimenopausal Transdermal Estradiol and Micronized Progesterone on Markers of Risk for Arterial Disease. J Clin Endocrinol Metab. 2020 May 1;105(5):e2050–e2060.
Journal cover image

Published In

J Clin Endocrinol Metab

DOI

EISSN

1945-7197

Publication Date

May 1, 2020

Volume

105

Issue

5

Start / End Page

e2050 / e2060

Location

United States

Related Subject Headings

  • Vascular Diseases
  • Treatment Outcome
  • Transdermal Patch
  • Risk Factors
  • Progesterone
  • Placebos
  • Perimenopause
  • Middle Aged
  • Humans
  • Female